Etrasimod

Etrasimod
	Skeletal formula of etrasimod
Clinical data
Trade names	Velsipity
Other names	APD334, APD-334
License data	US DailyMed: Etrasimod;
Routes of; administration	By mouth
Drug class	Sphingosine-1-phosphate receptor modulator
ATC code	None;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Protein binding	97.9%[medical citation needed]
Metabolism	Liver (CYP2C8, 2C9, 3A4)[medical citation needed]
Elimination half-life	30 hours[medical citation needed]
Excretion	Feces (82%), kidneys (5%)[medical citation needed]
Identifiers
	IUPAC name 2-[(3R)-7-{[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy}-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid;
CAS Number	1206123-37-6; as arginine: 1206123-97-8;
PubChem CID	44623998;
DrugBank	DB14766; as arginine: DBSALT003430;
ChemSpider	52084233; as arginine: 57643656;
UNII	6WH8495MMH; as arginine: MXE5EMA09L;
KEGG	D10930; as arginine: D10931;
ChEMBL	ChEMBL3358920;
Chemical and physical data
Formula	C26H26F3NO3
Molar mass	457.493 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CCC(C1)C2=C(C=C(C=C2)COC3=CC4=C(C=C3)NC5=C4CC[C@@H]5CC(=O)O)C(F)(F)F;
	InChI InChI=1S/C26H26F3NO3/c27-26(28,29)22-11-15(5-8-19(22)16-3-1-2-4-16)14-33-18-7-10-23-21(13-18)20-9-6-17(12-24(31)32)25(20)30-23/h5,7-8,10-11,13,16-17,30H,1-4,6,9,12,14H2,(H,31,32)/t17-/m1/s1; Key:MVGWUTBTXDYMND-QGZVFWFLSA-N;

Etrasimod, sold under the brand name Velsipity, is a medication that is used for the treatment of ulcerative colitis (UC).^[1] It is a selective sphingosine-1-phosphate (S1P) receptor modulator that modifies the activity of the immune system.^[1] It is taken by mouth.^[1]

Etrasimod was discovered by Arena Pharmaceuticals, with subsequent development by Pfizer.^[2]

Medical uses

Etrasimod is used for the treatment of moderate to severe ulcerative colitis.^[1]

Mechanism of action

It works by causing T cells to become trapped in the lymph nodes, preventing them from entering the bloodstream, from where they would travel to other tissues in the body and mediate inflammation.^[3]^[4]^[5]^[6]^[7]^[8]

Society and culture

Legal status

Velsipity was approved by the US Food and Drug Administration (FDA) in October 2023.^[1]^[9]^[10]

Names

Etrasimod is the international nonproprietary name.^[11]

References

^ ^a ^b ^c ^d ^e ^f Pfizer (12 October 2023). "Velsipity (etrasimod) tablets, for oral use" (PDF). U.S. Food and Drug Administration (FDA). Retrieved 18 October 2023.
^ Bayer M (2 May 2023). "Pfizer tosses newly acquired meds out of the Arena". Fierce Biotech. Retrieved 13 October 2023.
^ Atreya R, Neurath MF (April 2023). "The sphingosine-1-phosphate receptor agonist etrasimod in ulcerative colitis". Lancet. 401 (10383): 1132–1133. doi:10.1016/S0140-6736(23)00228-3. PMID 36871570.
^ Sandborn WJ, Vermeire S, Peyrin-Biroulet L, Dubinsky MC, Panes J, Yarur A, et al. (April 2023). "Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies". Lancet. 401 (10383): 1159–1171. doi:10.1016/S0140-6736(23)00061-2. PMID 36871574.
^ Dal Buono A, Gabbiadini R, Alfarone L, Solitano V, Repici A, Vetrano S, et al. (July 2022). "Sphingosine 1-Phosphate Modulation in Inflammatory Bowel Diseases: Keeping Lymphocytes Out of the Intestine". Biomedicines. 10 (7). doi:10.3390/biomedicines10071735. PMC 9313037. PMID 35885040.{{cite journal}}: CS1 maint: unflagged free DOI (link)
^ Argollo M, Furfaro F, Gilardi D, Roda G, Allocca M, Peyrin-Biroulet L, et al. (April 2020). "Modulation of sphingosine-1-phosphate in ulcerative colitis". Expert Opin Biol Ther. 20 (4): 413–420. doi:10.1080/14712598.2020.1732919. PMID 32093531.
^ Al-Shamma H, Lehmann-Bruinsma K, Carroll C, Solomon M, Komori HK, Peyrin-Biroulet L, et al. (June 2019). "The Selective Sphingosine 1-Phosphate Receptor Modulator Etrasimod Regulates Lymphocyte Trafficking and Alleviates Experimental Colitis". J Pharmacol Exp Ther. 369 (3): 311–317. doi:10.1124/jpet.118.254268. PMID 30872391.
^ Peyrin-Biroulet L, Christopher R, Behan D, Lassen C (May 2017). "Modulation of sphingosine-1-phosphate in inflammatory bowel disease". Autoimmun Rev. 16 (5): 495–503. doi:10.1016/j.autrev.2017.03.007. PMID 28279838.
^ Brooks M (13 October 2023). "FDA Approves New Drug for Ulcerative Colitis". Medscape. Retrieved 13 October 2023.
^ https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/216956Orig1s000ltr.pdf
^ World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 78". WHO Drug Information. 31 (3). hdl:10665/330961.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[Velsipity_FDA_label-1] ^ ^a ^b ^c ^d ^e ^f Pfizer (12 October 2023). "Velsipity (etrasimod) tablets, for oral use" (PDF). U.S. Food and Drug Administration (FDA). Retrieved 18 October 2023.

[Fierce-2] Bayer M (2 May 2023). "Pfizer tosses newly acquired meds out of the Arena". Fierce Biotech. Retrieved 13 October 2023.

[pmid36871570-3] Atreya R, Neurath MF (April 2023). "The sphingosine-1-phosphate receptor agonist etrasimod in ulcerative colitis". Lancet. 401 (10383): 1132–1133. doi:10.1016/S0140-6736(23)00228-3. PMID 36871570.

[pmid36871574-4] Sandborn WJ, Vermeire S, Peyrin-Biroulet L, Dubinsky MC, Panes J, Yarur A, et al. (April 2023). "Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies". Lancet. 401 (10383): 1159–1171. doi:10.1016/S0140-6736(23)00061-2. PMID 36871574.

[pmid35885040-5] Dal Buono A, Gabbiadini R, Alfarone L, Solitano V, Repici A, Vetrano S, et al. (July 2022). "Sphingosine 1-Phosphate Modulation in Inflammatory Bowel Diseases: Keeping Lymphocytes Out of the Intestine". Biomedicines. 10 (7). doi:10.3390/biomedicines10071735. PMC 9313037. PMID 35885040.{{cite journal}}: CS1 maint: unflagged free DOI (link)

[pmid32093531-6] Argollo M, Furfaro F, Gilardi D, Roda G, Allocca M, Peyrin-Biroulet L, et al. (April 2020). "Modulation of sphingosine-1-phosphate in ulcerative colitis". Expert Opin Biol Ther. 20 (4): 413–420. doi:10.1080/14712598.2020.1732919. PMID 32093531.

[pmid30872391-7] Al-Shamma H, Lehmann-Bruinsma K, Carroll C, Solomon M, Komori HK, Peyrin-Biroulet L, et al. (June 2019). "The Selective Sphingosine 1-Phosphate Receptor Modulator Etrasimod Regulates Lymphocyte Trafficking and Alleviates Experimental Colitis". J Pharmacol Exp Ther. 369 (3): 311–317. doi:10.1124/jpet.118.254268. PMID 30872391.

[pmid28279838-8] Peyrin-Biroulet L, Christopher R, Behan D, Lassen C (May 2017). "Modulation of sphingosine-1-phosphate in inflammatory bowel disease". Autoimmun Rev. 16 (5): 495–503. doi:10.1016/j.autrev.2017.03.007. PMID 28279838.

[Medscape-9] Brooks M (13 October 2023). "FDA Approves New Drug for Ulcerative Colitis". Medscape. Retrieved 13 October 2023.

[10] ttps://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/216956Orig1s000ltr.pdf

[11] World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 78". WHO Drug Information. 31 (3). hdl:10665/330961.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]